Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director K. Anand received an automatic grant of 600.7104 Deferred Stock Units as part of her director compensation. These units reflect cash retainer fees she chose to defer under the Company’s Directors' Deferral Plan, using a grant-date Elanco common stock price of $23.93.
Each Deferred Stock Unit is economically equivalent to one share of Elanco common stock and will be settled in stock when she separates from the Board. Following this award, she holds a total of 9,495.4518 Deferred Stock Units directly.
Elanco Animal Health Inc amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares of Elanco common stock. The filing states that Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries report beneficial ownership separately. The form is signed by Ashley Grim on 03/26/2026.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health reported that President and CEO Jeffrey N. Simmons received a grant of 117.887 deferred stock units on 2026-03-20. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this grant, Simmons directly holds a total of 23,795.2703 deferred stock units, which will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 61.5901 deferred stock units tied to common stock. These units are part of an Executive Deferral and Stock Match Plan and will settle in cash or shares after employment ends or in a specified future year. Following this award, Modi holds 9,072.9178 deferred stock units.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.216 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent. Following this grant, his reported deferred stock unit balance is 48.7929 units. These units will settle in cash or stock after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, so this filing reflects compensation rather than an open‑market trade.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health executive Rajeev A. Modi received a grant of 1,360.2363 deferred stock units on Company common stock as compensation. The grant was valued at $23.36 per unit and increased his directly held deferred stock units to 9,011.3277.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan, making this a routine, non‑market award rather than an open‑market purchase.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc President and CEO Jeffrey N. Simmons received a grant of 4,497.6194 deferred stock units linked to the company’s common stock. Each unit represents the right to receive one share of common stock or the cash equivalent in the future, typically after employment ends or in a specified year. Following this award, his reported deferred stock unit balance is 23,677.3833 units, reflecting compensation rather than an open-market stock purchase or sale.
Elanco Animal Health executive vice president and CFO Robert M. VanHimbergen reported a compensation-related grant of deferred stock units. He acquired 9.485 deferred stock units tied to Company common stock, bringing his direct holding in this award type to 40.5769 units. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent, settling in cash or shares after employment ends or in a specified future year under the Executive Deferral and Stock Match Plan.
Correia de Simas Jose Manuel reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health officer Correia de Simas Jose Manuel received a grant of 17,637.8425 deferred stock units on Company common stock at a reference value of $23.36 per unit. Following this award, he holds 22,280.4709 deferred stock units. These units will be settled in cash or shares after employment ends or in a designated future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc officer Rajeev A. Modi reported a tax-related share disposition. On 2026-03-03, he disposed of 4,392 shares of common stock through a tax-withholding disposition at $24.88 per share, leaving 155,901 shares held with direct ownership after the transaction.